Last updated: February 26, 2026
What is ARTISS?
ARTISS is a fibrin sealant used to aid hemostasis and tissue adhesion during surgical procedures. It combines human plasma-derived fibrinogen and thrombin to promote clot formation. Approved primarily for sealing, fixation, and hemostasis in various surgical settings, its efficacy depends heavily on formulation components, especially excipients, which influence stability, application, and safety.
What is the current excipient composition of ARTISS?
ARTISS’s formulation includes:
- Human plasma-derived fibrinogen
- Human plasma-derived thrombin
- Calcium chloride (CaCl₂) as an activator
- Carriers like cryoprecipitate or other stabilizers
Key excipient considerations involve preserving active proteins, ensuring stability during storage and application, and minimizing immune reactions. Notably, ARTISS’s formulations lack synthetic excipients, relying on natural plasma components.
What are the primary roles of excipients in ARTISS?
Excipients in ARTISS serve functions such as:
- Stabilizing fibrinogen and thrombin during storage
- Facilitating rapid clot formation upon application
- Enhancing product shelf-life and storage stability
- Reducing immunogenic or allergic responses
- Ensuring homogeneity and ease of application
Given that ARTISS derives from human plasma, the focus remains on maintaining biological activity and reducing pathogen transmission risk.
How can excipient strategies enhance ARTISS's commercial prospects?
1. Improving Stability and Shelf-life
Current formulations require cold storage and have limited shelf life. Incorporating excipients such as sugar derivatives (e.g., trehalose) or amino acids (e.g., glycine) could stabilize plasma proteins at room temperature, expanding distribution channels and reducing logistic costs.
2. Reducing Immunogenicity
Synthetic or recombinant excipients can replace plasma-derived stabilizers. Polymers like polyethylene glycol (PEG) can shield immunogenic sites, decreasing allergic reactions and broadening patient eligibility.
3. Enhancing Application Features
Developing excipient-enhanced formulations, such as gel-based carriers or pre-filled, ready-to-use kits, can improve ease of use, reduce preparation time, and streamline surgical workflows.
4. Extending Shelf-life and Storage
Inclusion of preservatives or stabilizers like antioxidants (e.g., ascorbic acid) can prolong product stability, especially for remote or resource-limited settings. This strategy aligns with the growing demand for ready-to-use, room-temperature-stable biotherapeutics.
What are the regulatory considerations?
Regulatory approval for excipient modifications requires demonstrating safety, efficacy, and stability. For plasma-derived products like ARTISS, changes to excipient composition trigger regulatory review under frameworks such as the European Medicine Agency (EMA) or the U.S. Food and Drug Administration (FDA). Replacing natural stabilizers with synthetic ones necessitates comprehensive safety data and may delay approval timelines.
What commercial opportunities exist for excipient innovations in ARTISS?
1. Market Expansion in Developing Countries
Room-temperature stable formulations reduce logistic hurdles, making ARTISS more accessible in regions with limited cold chain infrastructure.
2. Product Differentiation
Innovations in excipient formulations can distinguish ARTISS from competitors, emphasizing improved safety, ease of use, and storage.
3. Line Extensions and New Indications
Formulating variants with tailored excipients can enable specialized applications, such as pediatric surgeries or minimally invasive procedures, broadening market reach.
4. Partnerships with Excipient Suppliers
Collaborations with companies specializing in stabilizers, preservatives, and bio-compatible polymers can accelerate innovation and reduce R&D costs.
What are the competitive landscape considerations?
Major competitors include Tisseel (Baxter), coagulation products like Evicel (Johnson & Johnson), and emerging recombinant fibrin sealants. These products often utilize different excipient formats, with some employing synthetic stabilizers to improve shelf life and safety profiles. ARTISS’s reliance on plasma components limits differentiation, but advances in excipient formulation could create a competitive edge.
Summary of key excipient strategies:
| Focus Area |
Potential Excipients |
Commercial Impact |
| Stability enhancement |
Trehalose, glycine, PEG |
More stable, room-temperature formulations |
| Immunogenicity reduction |
Synthetic polymers, PEGylation |
Broader patient eligibility, reduced allergic reactions |
| Application ease |
Gel-based carriers, pre-filled kits |
Increased surgical workflow efficiency |
| Shelf-life extension |
Antioxidants, preservatives |
Improved logistics, expanded markets |
Key Takeaways
- ARTISS’s formulation centers on plasma-derived plasma proteins, with excipients primarily ensuring stability and application efficacy.
- Strategic incorporation of synthetic excipients can enhance stability, reduce immunogenicity, and expand global markets.
- Regulatory pathways for excipient modifications demand comprehensive safety and stability data.
- Innovation in excipient formulation presents opportunities for product differentiation, line extensions, and partnership development.
- Market expansion is possible through improved storage compatibility, especially in resource-limited settings.
FAQs
1. Can ARTISS formulations be modified with synthetic excipients without regulatory hurdles?
Modifications require regulatory review; use of synthetic excipients must demonstrate safety and efficacy, potentially delaying approval.
2. What excipients are commonly used in synthetic fibrin sealants?
Polymers like PEG, hyaluronic acid derivatives, and sugars such as trehalose serve as stabilizers or carriers.
3. How does excipient choice affect the immunogenicity of fibrin sealants?
Natural plasma-derived excipients carry immunogenic risks; synthetic or advanced stabilizers can reduce this, broadening patient eligibility.
4. Is room-temperature stability feasible for plasma-based fibrin sealants?
Yes; stabilizers like trehalose or PEG can improve thermal stability, but require validation for safety and efficacy.
5. What are the main barriers to excipient innovation in plasma-derived products?
Regulatory approvals, safety concerns, and potential impacts on product purity and consistency.
References
- Johnson, S. (2022). Advances in fibrin sealant formulations. Journal of Surgical Biomaterials, 38(4), 245–262.
- European Medicines Agency. (2022). Guidance on plasma-derived medicinal products.
- U.S. Food and Drug Administration. (2022). Regulatory considerations for biologics containing excipients.
- Smith, A., & Lee, K. (2021). Stabilization techniques for plasma proteins in hemostatic agents. BioProcessing International, 19(6), 44–52.]
